Press releases

NORTH CHICAGO, Ill., Nov. 3, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall impact of rheumatologic diseases from more than 40 abstracts, including three oral presentations, will be presented at the 2015 American College of Rheumatology (ACR) Annual Meeting, Nov. 7-11, in San Francisco. These data reinforce AbbVie's continued leadership in immunology and commitment to those living with a variety of inflammatory diseases.

NORTH CHICAGO, Ill., Nov. 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 24^th Annual Healthcare Conference on Wednesday, Nov. 11, 2015. Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at 11 a.m. Central time.

NORTH CHICAGO, Ill., Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) today outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial metrics over its long-range plan, through 2020.

NORTH CHICAGO, Ill., Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2015.

NORTH CHICAGO, Ill., Oct. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that IMBRUVICA^® (ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent. IMBRUVICA won this distinction out of 24 category nominees, all of which were deemed innovative in the field of medicine and were approved by the U.S. Food and Drug Administration (FDA) within the past five years. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

NORTH CHICAGO, Ill., Oct. 22, 2015 /PRNewswire/ -- In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) have been updated from ‘not recommended in Child-Pugh B patients’ to a contraindication in patients with Child-Pugh B cirrhosis. Patients classified as Child-Pugh C will remain contraindicated as they have been since approval.

- AbbVie launches Voices of HS at EADV to increase awareness and support for millions of people impacted by hidradenitis suppurativa (HS)

NORTH CHICAGO, Ill., Oct. 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2015 financial results on Friday, Oct. 30, 2015, before the market opens.

NORTH CHICAGO, Ill., Oct. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that 26 abstracts on HUMIRA^® (adalimumab) and hidradenitis suppurativa (HS), psoriasis and psoriatic arthritis will be presented at the European Academy of Dermatology and Venereology (EADV) Congress, Oct. 7 – 11, in Copenhagen, Denmark.

NORTH CHICAGO, Ill., Oct. 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical development program have been accepted for presentation at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco from November 13-17, further demonstrating AbbVie's strong leadership and ongoing commitment to patients with chronic hepatitis C virus (HCV) infection.